Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R01 - Clinical Trial Optional)

US National Institutes of Health (NIH) grant open #PAR-25-265

Response due Nov 16, 2027 · 00:00 UTC

Summary

This is a National Institutes of Health (NIH) funding opportunity announcement (PAR-25-265) soliciting R01 research grant applications focused on innovative screening approaches and therapies for screenable disorders in newborns. The opportunity is open to clinical trial proposals on an optional basis. The program seeks to advance newborn screening science and therapeutic development for conditions detectable at birth. The opportunity window spans nearly three years, from December 2024 through November 2027.

What they want

Technical requirements

Clinical trial inclusion is optional (not required)
Must align with R01 grant mechanism requirements
Research must address screening approaches and/or therapies for newborn screenable disorders

How they evaluate

Submission: Grants.gov federal grants portal (electronic submission)

Risks & flags

No dollar value or budget ceiling stated — award size unknown
Multi-year open window (3 years) with rolling submissions makes competitive landscape opaque
Document type listed as 'synopsis' only — full program announcement details not provided in source text

Market context

inferred from NAICS

Professional, Scientific & Technical Services

NAICS 541714

US market size: $2.0T
Typical award: $25K – $50M

Typical buyers

All federal civilianDoDStates

Commonly required

8(a)WOSBSDVOSBPE/PMP

Sector-level estimate — full code lookup not yet in catalog.

Innovative Screening Approaches and Therap…

Due Nov 16

Onboard ↗